Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

139.10CHF
4:09pm GMT
Change (% chg)

CHF0.10 (+0.07%)
Prev Close
CHF139.00
Open
CHF139.00
Day's High
CHF140.30
Day's Low
CHF138.20
Volume
14,600
Avg. Vol
21,807
52-wk High
CHF181.80
52-wk Low
CHF129.20

Chart for

About

COSMO Pharmaceuticals SA is a Luxembourg-based pharmaceutical company engaged in the development and production of drugs against selected gastrointestinal diseases. Its clinical research aims to treat Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease, as well as colon infections and skin... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): €1,965.91
Shares Outstanding(Mil.): 15.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Cosmo Pharmaceuticals: update on commercialization of Rifamycin SV MMX

* ‍ITS PARTNER DR. FALK PHARMA HAS FILED FOR MARKETING AUTHORIZATION OF RIFAFALK 200MG IN GERMANY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Nov 2017

BRIEF-Cosmo Pharmaceuticals: update on lawsuit against patent infringement on Uceris‍​

* DISTRICT OF DELAWARE HAS RULED NON-INFRINGEMENT OF ACTAVIS ANDA PRODUCT FOR GENERIC VERSION OF VALEANT’S UCERIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Nov 2017

BRIEF-Cosmo Pharmaceuticals and Fujifilm establish distribution agreement for Eleview for Europe & South Africa

* WITH FUJIFILM ESTABLISH DISTRIBUTION AGREEMENT FOR ELEVIEW® FOR EUROPE & SOUTH AFRICA​

25 Oct 2017

BRIEF-Cosmo Pharmaceuticals: FDA grants QIDP and fast track designations for Aemcolo​

* ‍FDA GRANTS COSMO PHARMACEUTICALS BOTH QIDP AND FAST TRACK DESIGNATIONS FOR AEMCOLO​ Source text - http://bit.ly/2zvcXIc Further company coverage: (Gdynia Newsroom)

23 Oct 2017

BRIEF-Cosmo Pharmaceuticals says ‍FDA accepts new drug application submission for methylene blue mmx​

* ‍FDA ACCEPTS NEW DRUG APPLICATION SUBMISSION FOR COSMO PHARMACEUTICAL'S METHYLENE BLUE MMX(TM)​

05 Oct 2017

BRIEF-Cosmo Pharmaceuticals and Olympus America establish co-promotion agreement for Eleview

* COSMO PHARMACEUTICALS AND OLYMPUS AMERICA INC. ESTABLISH CO-PROMOTION AGREEMENT FOR ELEVIEW(TM) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

03 Oct 2017

BRIEF-Cosmo Pharmaceuticals swings to H1 ‍operating loss of EUR 8.4 mln

* ‍H1 REVENUE OF EUR 31.8 MILLION COMPARED TO EUR 31.6 MILLION IN PRIOR YEAR​

28 Jul 2017

BRIEF-Cosmo announces European approval of Qolotag for sigmoidoscopies in IBD patients

* COSMO PHARMACEUTICALS NV - COSMO ANNOUNCES EUROPEAN APPROVAL OF QOLOTAG® FOR SIGMOIDOSCOPIES IN IBD PATIENTS

26 Jul 2017

BRIEF-Cosmo Pharmaceuticals submits to FDA new drug application for LuMeBlue‍​

* ANNOUNCES SUBMISSION TO FDA OF NEW DRUG APPLICATION FOR LUMEBLUE‍​ Source text - http://bit.ly/2uoLUPd Further company coverage: (Gdynia Newsroom)

24 Jul 2017

BRIEF-Cosmo says Remimazolam successfully concludes late-stage trial

* Says Remimazolam successfully concludes phase iii clinical trial for procedural sedation in bronchoscopy

29 Jun 2017

Earnings vs. Estimates

No consensus analysis data available.